MannKind(NASDAQ) MNKD

MannKind Corporation helps people manage diabetes and lung diseases. It makes portable inhalers and wearable devices for taking medicine. These products allow patients to treat themselves at home.

What MannKind Makes

• Afrezza: Inhaled ultra-rapid human insulin used by adults and children aged six and older to control blood sugar levels.
• Furoscix: Subcutaneous medicine delivered via a wearable infusor to treat fluid buildup in patients with heart or kidney disease.
• V-Go: Mechanical patch-like device that provides a continuous flow of insulin throughout the day and extra doses at mealtimes.
• Tyvaso DPI: Inhaled dry powder treatment for high blood pressure in the lungs, developed and marketed with United Therapeutics.
• Collaboration and Royalties: Revenue generated from manufacturing products for partners and a 9% royalty on net sales of Tyvaso DPI.

Growing the Portfolio

• Acquired the V-Go mechanical insulin delivery system from Zealand Pharma in May 2022.
• Purchased scPharma in October 2025 to add the Furoscix product line to its cardiometabolic business.
• Expanded a partnership with United Therapeutics in August 2025 to develop a dry-powder version of the drug ralinepag.
• Received FDA approval for Furoscix ReadyFlow, a high-concentration autoinjector, on July 23, 2026.
• Launched Afrezza in India through a supply agreement with Cipla starting in December 2025.

Innovative Delivery Systems

MannKind uses proprietary dry-powder technology to turn medicine into tiny particles that patients can inhale easily into their lungs. This approach allows drugs like insulin to enter the bloodstream quickly without the need for traditional needle injections.

Measuring the Progress

• Total revenue reached $109.4 million for the three months ended June 30, 2026.
• Commercial product gross profit rose 54% to $27.6 million during the three-month period ended June 30, 2026.
• Selling, general and administrative expenses increased 84% to $58.3 million for the three months ended June 30, 2026.
• Net revenue from Furoscix sales was $22.2 million during the three months ended June 30, 2026.
• The company held $111.1 million in cash, cash equivalents, and investments as of June 30, 2026.

The Path Forward

MannKind has evolved from a single-product company to a diversified biopharmaceutical firm with multiple revenue streams from its own sales and global partnerships. Its expansion into orphan lung diseases and home-based heart failure treatments demonstrates its focus on specialized medical niches.